Does the media refer more to CGEM or GRFS?

In the previous week, Cullinan Therapeutics had 14 more articles in the media than Grifols. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 4 mentions for Grifols. Grifols' average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.71 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or CGEM?

In the previous week, Cullinan Therapeutics had 3 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 15 mentions for CRISPR Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.71 beat CRISPR Therapeutics' score of 0.68 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PBLS or CGEM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A

Is PBLS or CGEM more profitable?

Parabilis Medicines' return on equity of 0.00% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Parabilis Medicines N/A N/A N/A Cullinan Therapeutics N/A -52.89% -48.18%

Does the media prefer PBLS or CGEM?

In the previous week, Cullinan Therapeutics had 13 more articles in the media than Parabilis Medicines. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 5 mentions for Parabilis Medicines. Cullinan Therapeutics' average media sentiment score of 0.71 beat Parabilis Medicines' score of 0.58 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CGEM or ACAD?

In the previous week, Cullinan Therapeutics had 14 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Cullinan Therapeutics' score of 0.71 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, CGEM or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is CGEM or EWTX more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Edgewise Therapeutics N/A -39.01% -36.96%

Does the media favor CGEM or EWTX?

In the previous week, Cullinan Therapeutics had 15 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Cullinan Therapeutics' score of 0.71 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cullinan Therapeutics (CGEM) Competitors

$21.08 -0.28 (-1.31%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$20.63 -0.45 (-2.13%)

As of 09/18/2026 07:30 PM Eastern

Compare

CGEM vs. GRFS, CRSP, PBLS, ACAD, and EWTX

Should you buy Cullinan Therapeutics stock or one of its competitors? Cullinan Therapeutics's main competitors and comparable companies include Grifols (GRFS), CRISPR Therapeutics (CRSP), Parabilis Medicines (PBLS), ACADIA Pharmaceuticals (ACAD), and Edgewise Therapeutics (EWTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cullinan Therapeutics compare to Grifols?

Cullinan Therapeutics (NASDAQ:CGEM) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cullinan Therapeutics presently has a consensus price target of $33.00, suggesting a potential upside of 56.55%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 36.80%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cullinan Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Grifols has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Grifols	$8.51B	0.58	$454.82M	$0.19	38.47

Grifols has a net margin of 5.54% compared to Cullinan Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Grifols	5.54%	6.21%	2.39%

Cullinan Therapeutics has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

In the previous week, Cullinan Therapeutics had 14 more articles in the media than Grifols. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 4 mentions for Grifols. Grifols' average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.71 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	6 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Grifols beats Cullinan Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cullinan Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Cullinan Therapeutics (NASDAQ:CGEM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

CRISPR Therapeutics currently has a consensus price target of $67.94, indicating a potential upside of 20.12%. Cullinan Therapeutics has a consensus price target of $33.00, indicating a potential upside of 56.55%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.59
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

Cullinan Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,558.06	-$581.60M	-$4.76	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Cullinan Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cullinan Therapeutics had 3 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 15 mentions for CRISPR Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.71 beat CRISPR Therapeutics' score of 0.68 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	6 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cullinan Therapeutics beats CRISPR Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Cullinan Therapeutics (NASDAQ:CGEM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Parabilis Medicines presently has a consensus target price of $41.67, indicating a potential downside of 0.15%. Cullinan Therapeutics has a consensus target price of $33.00, indicating a potential upside of 56.55%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Parabilis Medicines' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Cullinan Therapeutics	N/A	-52.89%	-48.18%

In the previous week, Cullinan Therapeutics had 13 more articles in the media than Parabilis Medicines. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 5 mentions for Parabilis Medicines. Cullinan Therapeutics' average media sentiment score of 0.71 beat Parabilis Medicines' score of 0.58 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	6 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cullinan Therapeutics beats Parabilis Medicines on 7 of the 9 factors compared between the two stocks.

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Cullinan Therapeutics (NASDAQ:CGEM) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Cullinan Therapeutics has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
ACADIA Pharmaceuticals	$1.07B	4.39	$391M	$2.22	12.29

Cullinan Therapeutics presently has a consensus price target of $33.00, indicating a potential upside of 56.55%. ACADIA Pharmaceuticals has a consensus price target of $34.36, indicating a potential upside of 25.91%. Given Cullinan Therapeutics' higher probable upside, equities research analysts plainly believe Cullinan Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Cullinan Therapeutics had 14 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Cullinan Therapeutics' score of 0.71 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	6 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Cullinan Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Summary

ACADIA Pharmaceuticals beats Cullinan Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

In the previous week, Cullinan Therapeutics had 15 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Cullinan Therapeutics' score of 0.71 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	6 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics' return on equity of -39.01% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Cullinan Therapeutics presently has a consensus price target of $33.00, indicating a potential upside of 56.55%. Edgewise Therapeutics has a consensus price target of $50.33, indicating a potential upside of 11.06%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Cullinan Therapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Summary

Edgewise Therapeutics beats Cullinan Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.36B	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-6.80	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	3.05	15.45	10.46	6.33
Net Income	-$219.88M	-$22.86M	$3.49B	$358.33M
7 Day Performance	2.38%	-1.21%	0.59%	1.12%
1 Month Performance	-6.39%	-4.42%	-2.01%	-2.67%
1 Year Performance	240.00%	37.81%	18.09%	6.01%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	3.3725 of 5 stars	$21.08 -1.3%	$33.00 +56.5%	+232.5%	$1.36B	N/A	N/A	109	High Trading Volume
GRFS Grifols	4.8349 of 5 stars	$7.79 -0.2%	$10.00 +28.5%	-25.6%	$5.30B	$8.51B	40.99	25,247	News Coverage Analyst Upgrade
CRSP CRISPR Therapeutics	2.413 of 5 stars	$54.70 -1.9%	$68.06 +24.4%	-10.1%	$5.27B	$3.51M	N/A	460
PBLS Parabilis Medicines	1.5724 of 5 stars	$39.54 -2.2%	$41.67 +5.4%	N/A	$4.88B	N/A	N/A	N/A	News Coverage
ACAD ACADIA Pharmaceuticals	4.436 of 5 stars	$27.86 -0.6%	$34.36 +23.3%	+10.3%	$4.79B	$1.07B	12.52	510

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. GRFS, CRSP, PBLS, ACAD, and EWTX

How does Cullinan Therapeutics compare to Grifols?

Summary

How does Cullinan Therapeutics compare to CRISPR Therapeutics?

Summary

How does Cullinan Therapeutics compare to Parabilis Medicines?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. GRFS, CRSP, PBLS, ACAD, and EWTX

How does Cullinan Therapeutics compare to Grifols?

Do institutionals & insiders have more ownership in CGEM or GRFS?

Do analysts recommend CGEM or GRFS?

Which has higher earnings and valuation, CGEM or GRFS?

Is CGEM or GRFS more profitable?

Which has more risk and volatility, CGEM or GRFS?

Does the media refer more to CGEM or GRFS?

Summary

How does Cullinan Therapeutics compare to CRISPR Therapeutics?

Do analysts prefer CRSP or CGEM?

Which has more risk and volatility, CRSP or CGEM?

Which has stronger earnings and valuation, CRSP or CGEM?

Is CRSP or CGEM more profitable?

Do insiders & institutionals believe in CRSP or CGEM?

Does the media favor CRSP or CGEM?

Summary

How does Cullinan Therapeutics compare to Parabilis Medicines?

Do analysts rate PBLS or CGEM?

Do institutionals and insiders believe in PBLS or CGEM?

Which has preferable valuation and earnings, PBLS or CGEM?

Is PBLS or CGEM more profitable?

Does the media prefer PBLS or CGEM?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Which has more volatility and risk, CGEM or ACAD?

Which has better valuation and earnings, CGEM or ACAD?

Do analysts rate CGEM or ACAD?

Does the media refer more to CGEM or ACAD?

Do insiders and institutionals hold more shares of CGEM or ACAD?

Is CGEM or ACAD more profitable?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Do institutionals & insiders believe in CGEM or EWTX?

Which has stronger earnings & valuation, CGEM or EWTX?

Does the media favor CGEM or EWTX?

Is CGEM or EWTX more profitable?

Do analysts prefer CGEM or EWTX?

Which has more volatility & risk, CGEM or EWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools